Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mercury Laboratories's quarterly market cap
declined
from Dec. 2025 (₹973.4 Mil) to Mar. 2026 (₹840.0 Mil) but then
increased
from Mar. 2026 (₹840.0 Mil) to Jun. 2026 (₹944.0 Mil).
Mercury Laboratories's annual market cap
declined
from Mar. 2024 (₹998.5 Mil) to Mar. 2025 (₹982.9 Mil) and
declined
from Mar. 2025 (₹982.9 Mil) to Mar. 2026 (₹840.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mercury Laboratories's Enterprise Value for Today is ₹994.9 Mil.
Mercury Laboratories (BOM:538964) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Mercury Laboratories Market Cap Related Terms
Mercury Laboratories Market Cap Historical Data
* Premium members only.
The historical data trend for Mercury Laboratories's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Laboratories's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Laboratories Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Laboratories's Market Cap distribution charts can be found below:
* The bar in red indicates where Mercury Laboratories's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Mercury Laboratories's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mercury Laboratories (BOM:538964) has a Market Cap of ₹975.0 Mil as of Aug. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mercury Laboratories and its competitors. According to the industry distribution chart, Mercury Laboratories ranks #877 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 85.6%.
Is Mercury Laboratories' Market Cap too high?
Mercury Laboratories' current Market Cap is ₹975.0 Mil. Based on the distribution chart, Mercury Laboratories ranks #877 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mercury Laboratories has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mercury Laboratories' Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mercury Laboratories ranks #877 out of 1024 companies for Market Cap. This places Mercury Laboratories in the lower half of its industry. The industry median Market Cap is 214.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 214.68, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Mercury Laboratories and its competitors. For the Drug Manufacturers industry, the median Market Cap is 214.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercury Laboratories's current Market Cap is ₹975.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Mercury Laboratories (BOM:538964) is currently considered Fairly Valued. The stock's GF Value™ is ₹832.71, compared to a current price of ₹812.50 — trading 2.4% below its estimated fair value. The current Market Cap is ₹975.0 Mil. Mercury Laboratories' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Mercury Laboratories (BOM:538964), the current Market Cap is ₹975.0 Mil as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Laboratories (BOM:538964) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Laboratories stock appears to be undervalued.
The current stock price of ₹812.50 is trading 2.4% below its estimated GF Value™ of ₹832.71.
GuruFocus considers Mercury Laboratories to be Fairly Valued.
Key valuation signals for BOM:538964:
Market Cap: ₹975.0 Mil
GF Value™: ₹832.71 vs. price of ₹812.50 (2.4% below fair value)
No single metric tells the full story. See the BOM:538964 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and distribution of pharmaceutical drugs, herbs, and laboratory and surgical materials. The group produces medicines and formulations in the segments of pediatrics, obstetrics, gynecology, surgeon segment, multivitamin and nutrition supplements, antibiotics, and others. The company sells its products in India and Internationally, of which key revenue is derived from sales made in India.
76GF Score
Get the complete analysis for BOM:538964
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538964 has been successfully added to your 
